轻度脂肪酶升高与急性胰腺炎及胰腺癌远期风险
多中心回顾性队列研究纳入9447例患者(5851例轻度脂肪酶升高无急性胰腺炎,3596例腹痛但脂肪酶正常且影像内镜实验室正常),随访至少10年。轻度脂肪酶升高是急性胰腺炎的独立预测因素(2.8% vs 1.2%,OR 2.6,P<0.001),但与胰腺癌风险无关(0.4% vs 0.3%,OR 0.7,P=0.38)。
要点
- 轻度脂肪酶升高且无急性胰腺炎者,远期急性胰腺炎风险升高(2.8% vs 1.2%,OR 2.6)。
- 轻度脂肪酶升高未显示与胰腺癌风险增加相关(OR 0.7,P=0.38)。
- 对轻度脂肪酶升高患者应关注远期急性胰腺炎风险。
核心结论
- 轻度脂肪酶升高与远期急性胰腺炎风险增加独立相关,但与胰腺癌风险无关。
研究设计与样本
- 多中心回顾性队列研究,纳入9447例患者,轻度脂肪酶升高组5851例(无急性胰腺炎),无轻度脂肪酶升高组3596例(腹痛但脂肪酶、影像、内镜及实验室检查正常),随访至少10年。
主要发现
- 轻度脂肪酶升高组急性胰腺炎发生率为2.8%,无轻度脂肪酶升高组为1.2%,logistic回归显示轻度脂肪酶升高为急性胰腺炎独立预测因素(OR 2.6,P<0.001)。
- 轻度脂肪酶升高组胰腺癌发生率为0.4%,无轻度脂肪酶升高组为0.3%,两组无显著差异(OR 0.7,P=0.38)。
临床怎么用
- 对轻度脂肪酶升高但无急性胰腺炎的患者,应认识到其远期急性胰腺炎风险增加,可考虑相应随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Long-term risk of acute pancreatitis (AP) and pancreatic cancer (PC) with mildly elevated lipase (MEL) is not well established. METHODS: Multicenter retrospective cohort study-"MEL" group had MEL without AP; "no MEL" group had abdominal pain but normal lipase, imaging, endoscopy, and labs. Primary outcomes were incidence of AP or PC in MEL vs no MEL after at least 10-year follow-up. RESULTS: 9,447 patients met inclusion criteria (5,851 MEL, 3,596 no MEL). Logistic regression identified MEL as an independent predictor of AP (2.8% vs 1.2%, odds ratio 2.6, P < 0.001) but not PC (0.4% vs 0.3%, odds ratio 0.7, P 0.38). DISCUSSION: MEL was associated with increased long-term AP risk.
引用
- Ansari Z, Ahmad A, Jamal Al-Din T, et al. Mildly Elevated Lipase and Subsequent Risk of Acute Pancreatitis and Pancreatic Cancer. Am J Gastroenterol. 2025. PMID: 41308113. doi:10.14309/ajg.0000000000003850
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。